Nuvation Bio: Undervalued Growth Potential with Key Developments on the Horizon

JonesTrading analyst Soumit Roy has maintained their bullish stance on NUVB stock, giving a Buy rating today.

Soumit Roy has given his Buy rating due to a combination of factors that highlight Nuvation Bio’s potential for growth and market success. The company is poised to launch taletrectinib by mid-2025, contingent on FDA approval by the June 23 PDUFA date. This drug has been granted a priority review, and management is optimistic about a line-agnostic full approval, which would allow it to address a broader patient base.
Furthermore, Nuvation Bio is currently undervalued compared to its peers, presenting a buying opportunity for investors. The company is trading at a significantly lower enterprise value than its competitor, Nuvalent. Additionally, several key developments are anticipated in 2025, including FDA approval, initial revenue generation from taletrectinib, and promising Phase 2 data for another drug, safusidenib. These factors, combined with a strong commercialization team and favorable market research, underpin Roy’s positive outlook on Nuvation Bio.

In another report released today, Wedbush also maintained a Buy rating on the stock with a $5.00 price target.